Significance of PD1 Alternative Splicing in Celiac Disease as a Novel Source for Diagnostic and Therapeutic Target

被引:10
|
作者
Ponce de Leon, Candelaria [1 ]
Lorite, Pedro [1 ]
Angel Lopez-Casado, Miguel [2 ]
Barro, Francisco [3 ]
Palomeque, Teresa [1 ]
Isabel Torres, Maria [1 ]
机构
[1] Univ Jaen, Fac Hlth Sci, Dept Expt Biol, Jaen, Spain
[2] Virgen de las Nieves Hosp, Dept Pediat Gastroenterol, Granada, Spain
[3] Spanish Natl Res Council CSC, Inst Sustainable Agr, Dept Plant Genet Improvement, Cordoba, Spain
来源
FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷
关键词
PD1; PDL; celiac disease; alternative splicing; gluten peptides; immune checkpoint; SYSTEMIC-LUPUS-ERYTHEMATOSUS; T-CELL RESPONSES; PD-1; ASSOCIATION; EXPRESSION; GLUTEN; LIGANDS; PEPTIDE; PATHWAY; PDCD1;
D O I
10.3389/fimmu.2021.678400
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background We have focused on the alteration of the PD-1/PD-L1 pathway in celiac disease and discussed the roles of the PD1 pathway in regulating the immune response. We explored the idea that the altered mRNA splicing process in key regulatory proteins could represent a novel source to identify diagnostic, prognostic, and therapeutic targets in celiac disease. Methods We characterized the PD1 mRNA variants' profile in CD patients and in response to gluten peptides' incubation after in vitro experiments. Total RNA from whole blood was isolated, and the coding region of the human PD-1 mRNA was amplified by cDNA PCR. Results PCR amplification of the human PD-1 coding sequence revealed an association between the over-expression of the sPD-1 protein and the PD-1 Delta ex3 transcript in celiac disease. Thus, we have found three novel alternative spliced isoforms, two of which result in a truncated protein and the other isoform with a loss of 14 aa of exon 2 and complete exon 3 (Delta 3) which could encode a new soluble form of PD1 (sPD-1). Conclusions Our study provides evidence that dietary gluten can modulate processes required for cell homeostasis through the splicing of pre-mRNAs encoding key regulatory proteins, which represents an adaptive mechanism in response to different nutritional conditions.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] A pilot study of alternative TrkAIII splicing in Merkel cell carcinoma: a potential oncogenic mechanism and novel therapeutic target
    Lucia Cappabianca
    Stefano Guadagni
    Rita Maccarone
    Michela Sebastiano
    Alessandro Chiominto
    Antonietta Rosella Farina
    Andrew Reay Mackay
    Journal of Experimental & Clinical Cancer Research, 38
  • [22] Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy
    Schetters, Sjoerd T. T.
    Rodriguez, Ernesto
    Kruijssen, Laura J. W.
    Crommentuijn, Matheus H. W.
    Boon, Louis
    Van den Bossche, Jan
    Den Haan, Joke M. M.
    Van Kooyk, Yvette
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [23] LRG1 as a novel therapeutic target in eye disease
    De Rossi, Giulia
    Da Vitoria Lobo, Marlene E.
    Greenwood, John
    Moss, Stephen E.
    EYE, 2022, 36 (02) : 328 - 340
  • [24] LRG1 as a novel therapeutic target in eye disease
    Giulia De Rossi
    Marlene E. Da Vitoria Lobo
    John Greenwood
    Stephen E. Moss
    Eye, 2022, 36 : 328 - 340
  • [25] Sigma 1 receptor: A novel therapeutic target in retinal disease
    Smith, Sylvia B.
    Wang, Jing
    Cui, Xuezhi
    Mysona, Barbara A.
    Zhao, Jing
    Bollinger, Kathryn E.
    PROGRESS IN RETINAL AND EYE RESEARCH, 2018, 67 : 130 - 149
  • [26] Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics
    Kotraiah, Vinayaka
    Phares, Timothy W.
    Browne, Cecille D.
    Pannucci, James
    Mansour, Marc
    Noe, Amy R.
    Tucker, Kenneth D.
    Christen, Jayne M.
    Reed, Charles
    MacKay, Alecia
    Weir, Genevieve M.
    Rajagopalan, Rajkannan
    Stanford, Marianne M.
    Chung, Chun-Shiang
    Ayala, Alfred
    Huang, Jing
    Tsuji, Moriya
    Gutierrez, Gabriel M.
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [27] Clinical significance of PNO1 as a novel biomarker and therapeutic target of hepatocellular carcinoma
    Roy, Sanjit K.
    Srivastava, Shivam
    McCance, Caroline
    Shrivastava, Anju
    Morvant, Jason
    Shankar, Sharmila
    Srivastava, Rakesh K.
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2024, 28 (09)
  • [28] PARP1 INHIBITION AS A NOVEL THERAPEUTIC TARGET FOR KELOID DISEASE
    Park, Tae Hwan
    Park, Yun Joo
    WOUND REPAIR AND REGENERATION, 2019, 27 (03) : A40 - A40
  • [29] Correction: LRG1 as a novel therapeutic target in eye disease
    Giulia De Rossi
    Marlene E. Da Vitoria Lobo
    John Greenwood
    Stephen E. Moss
    Eye, 2023, 37 : 1517 - 1517
  • [30] PARP1 Inhibition as a Novel Therapeutic Target for Keloid Disease
    Park, Tae Hwan
    Kim, Chan Woo
    Choi, Jin Sik
    Park, Yun Joo
    Chong, Yosep
    Park, Min Ji
    Cho, Yuri
    ADVANCES IN WOUND CARE, 2019, 8 (05) : 186 - 194